PG-102

Phase 2Biologic

RRANI Therapeutics

PG-102 is one of 97 biologic programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

ObesityActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

PG-102

RRANI Therapeutics

Phase 2

2 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Type 2 Diabetes Mellitus

NCT07187856

Q2 2027

Phase 2Not yet recruiting

Type 2 Diabetes

NCT07677891

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Active, not recruiting·PProGen. Co., Ltd.·Phase 2·NCT06712615·144 enrolled

A Randomized, Open-Label, Multicenter, Active-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Switching From Once-Weekly Dulaglutide to Once-Monthly PG-102(MG12) in Patients With Type 2 Diabetes Mellitus Receiving Stable Dulaglutide Therapy

Not yet recruiting·PProGen. Co., Ltd.·Phase 2·NCT07677891·60 enrolled

Type 2 Diabetes Mellitus1 trial

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Not yet recruiting·PProGen. Co., Ltd.·Phase 2·NCT07187856·80 enrolled

Obesity1 trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

Completed·PProGen. Co., Ltd.·Phase 1·NCT06309667·102 enrolled

Unspecified1 trial

An Early Phase Study of RT-114

Not yet recruiting·RRANI Therapeutics·Phase 1·NCT06891287·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PG-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PG-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PG-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RANI Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: RRANI Therapeutics

PG-102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Type 2 Diabetes2 trials

Type 2 Diabetes Mellitus1 trial

Obesity1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News